skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

The effect of subcutaneous injection of methylprednisolone acetate and lidocaine for refractory postherpetic neuralgia: a prospective, observational study

Health science reports, 2021-06, Vol.4 (2), p.e271-n/a [Peer Reviewed Journal]

2021 The Authors. published by Wiley Periodicals LLC. ;2021 The Authors. Health Science Reports published by Wiley Periodicals LLC. ;2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2398-8835 ;EISSN: 2398-8835 ;DOI: 10.1002/hsr2.271 ;PMID: 33855194

Full text available

Citations Cited by
  • Title:
    The effect of subcutaneous injection of methylprednisolone acetate and lidocaine for refractory postherpetic neuralgia: a prospective, observational study
  • Author: Nguyen, Duc Thuan ; Dang, Thanh Chung ; Nguyen, Quang An ; Le, Trung Duc ; Hoang, Thi Dung ; Tran, Thi Ngoc Truong ; Duong, Ta Hai Ninh ; Nguyen, Van Tuan ; Le, Van Quan ; Hoang, Tien Ung ; Duong, Minh Tuan ; Nhu, Dinh Son ; Phan, Viet Nga
  • Subjects: Antidepressants ; lidocaine ; methylprednisolone acetate ; Pain ; Population ; Quality of life ; refractory postherpetic neuralgia ; Software ; subcutaneous injection
  • Is Part Of: Health science reports, 2021-06, Vol.4 (2), p.e271-n/a
  • Description: Background Postherpetic neuralgia (PHN) is the most common and bearable complication of herpes zoster (HZ). This pain may have negative impact on the patient's all aspects of daily life and health‐related quality of life (HRQOL). Despite numerous advances in treatment, many patients remain resistant to the current therapy options. It is the first time subcutaneous injection of methylprednisolone acetate and lidocaine has been used to treat refractory PHN. We report the results of this treatment evaluating pain relief and HRQOL improvement in this disorder. Methods A total of 43 patients with refractory PHN was enrolled in the observational study. All patients received daily subcutaneous injection of methylprednisolone acetate and lidocaine for 10 consecutive days. The severity of pain was assessed by using Visual Analog Scale (VAS), and 36‐Item Short Form Survey (SF‐36) was applied to evaluate HRQOL. Assessment of the pain and HRQOL was carried out at baseline and posttreatment at 4 weeks as well as 6 and 12 months. Results At baseline, all patients experienced severe PHN with average VAS scores of 8.44 ± 0.85 (minimum 7; maximum 10). At 4 weeks, 6 months, and 12 months after treatment, the pain had significantly decreased (P < .001), and all subjects showed significant improvement in all eight domains of HRQOL. No major adverse events associated with the subcutaneous injection were observed. Conclusions Our results indicate that subcutaneous injection of methylprednisolone acetate and lidocaine can be an effective and safe treatment for PHN.
  • Publisher: United States: John Wiley & Sons, Inc
  • Language: English
  • Identifier: ISSN: 2398-8835
    EISSN: 2398-8835
    DOI: 10.1002/hsr2.271
    PMID: 33855194
  • Source: PubMed Central
    Wiley Blackwell Open Access Titles
    ProQuest Central
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait